Enterprise Value
196B
Cash
10.94B
Avg Qtr Burn
N/A
Short % of Float
1.96%
Insider Ownership
0.25%
Institutional Own.
80.73%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KRYSTEXXA Details Chronic refractory gout | Approved Quarterly sales | |
Uplizna® (inebilizumab-cdon) Details Inflammatory disease | Approved Quarterly sales | |
TAVNEOS (Avacopan) (C5aR) Details ANCA-Associated Vasculitis, Autoimmune disease | Approved Quarterly sales | |
TEPEZZA Details Eye disease , Thyroid Eye Disease | Approved Quarterly sales | |
BLINCYTO® (blinatumomab) Details B-cell acute lymphoblastic leukemia | Approved Quarterly sales | |
BLINCYTO® (blinatumomab) Details B-cell acute lymphoblastic leukemia | PDUFA Approval decision | |
Tarlatamab (AMG 757) Details Small cell lung cancer, Lung cancer, Cancer | PDUFA Approval decision | |
LUMAKRAS/LUMYKRAS (sotorasib) Details Non-small cell lung carcinoma | sNDA Resubmission | |
Olpasiran (AMG 890) Details Atherosclerotic cardiovascular disease | Phase 3 Data readout | |
BLINCYTO® (blinatumomab) + Low intensity chemo Details B-cell acute lymphoblastic leukemia | Phase 3 Data readout | |
Bemarituzumab Details Gastric cancer | Phase 3 Data readout | |
Rocatinlimab Details Atopic dermatitis | Phase 3 Data readout | |
TEZSPIRE Details Chronic rhinosinusitis with nasal polyps | Phase 3 Data readout | |
Nplate® Details Chemo-induced thrombocytopenia | Phase 3 Data readout | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details IgG4-related disease | Phase 3 Data readout | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details Neuromuscular disease, Myasthenia gravis | Phase 3 Data readout | |
TAVNEOS (Avacopan) (C5aR) Details Skin disease/disorder, Hidradenitis suppurativa | Phase 3 Update | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Autoimmune disease, Cellulite | Phase 3 Initiation | |
LUMAKRAS + Vectibix and FOLFIRI Details Colorectal cancer , Cancer | Phase 3 Initiation | |
Fipaxalparant (AMG 670) (HZN-825) Details Idiopathic pulmonary fibrosis | Phase 2b Data readout | |
Bempikibart (ADX-914) Details Atopic dermatitis | Phase 2 Data readout | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Kidney transplantation, Kidney disease | Phase 2 Data readout | |
Dazodalibep (HZN-4920) Details Kidney disease, Lupus nephritis, Autoimmune disease | Phase 2 Data readout | |
Bempikibart (ADX-914) Details Alopecia areata | Phase 2 Data readout | |
UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details Kidney transplantation, Kidney disease | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Cutaneous lupus erythematosus | Phase 2 Data readout | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Alopecia areata | Phase 2 Data readout | |
Phase 2 Data readout | ||
Phase 2 Data readout | ||
Tezspire Details Chronic obstructive pulmonary disease | Phase 2 Data readout | |
TAVNEOS (Avacopan) (C5aR) Details Kidney disease, C3 Glomerulopathy | Phase 2 Update | |
Daxdilimab (HZN-7734) (VIB7734) (Anti-ILT7 mAb) Details Systemic lupus erythematosus | Phase 2 Update | |
Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details Arthritis, Congenital adrenal hyperplasia, Genetic disorder, Autoimmune disease, Rheumatoid arthritis | Phase 2 Update | |
HZN-457 Details Chronic refractory gout | Phase 1 Data readout | |
AMG 786 Details Obesity | Phase 1 Data readout |